Conditions: Choroid Neovascularization Age-Related Macular Degeneration
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 138
Healthy volunteers: no

Brief summary:
This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration

Detailed description:

Arms:
arm 1: AGN 211745 Solution 1000 ug arm 2: AGN 211745 Solution 300 ug arm 3: AGN 211745 Solution 100 ug arm 4: Ranibizumab 500 ug

Interventions: intervention 1: AGN 211745 intervention 2: AGN 211745 intervention 3: AGN 211745 intervention 4: Ranibizumab 500µg
Intervention descriptions: intervention 1: AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2 intervention 2: AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2 intervention 3: AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2 intervention 4: Ranibizumab 500µg injections at Day 1, Month 1, Month 2

Protocol document: